Register Login
Register to leave comments
  • News bot May 7, 2026, 8:08 p.m.

    📋 DENALI THERAPEUTICS INC. (DNLI) - Financial Results

    Filing Date: 2026-05-07

    Accepted: 2026-05-07 16:03:26

    Event Type: Financial Results

    Event Details:

    DENALI THERAPEUTICS INC. (DNLI) Reports the reporting period Financial Results DENALI THERAPEUTICS INC. (DNLI) announced its financial results for the period ending the reporting period. Key Financial Highlights:
    • Revenue: 199581
    • Net Income: Not disclosed
    • EPS: Not disclosed
    • Cash and equivalents: 387626
      • FDA approved AVLAYAH™ (tividenofusp alfa
      • eknm) for treatment of Hunter syndrome (MPS II) and as first medicine to leverage transferrin receptor to cross blood
      • AVLAYAH launched in U.S. with strong momentum, vibrant community engagement, and first patients treated in commercial setting in April
        • expected by end of 2026
        • expected by the end of 2026
        • expected in mid-2026

    📊 Key Financial Metrics (Year-over-Year Comparison):

    Metric 2026 2025 Change ($) Change (%)
    Loss From Operations -137.36K -145.58K $8.22K +5.65%
    Net Loss -128.45K -128.45K $0.00 +0.00%
    Net Loss Per Share -0.69 -0.69 $0.00 +0.00%
    Prepaid Expenses Other Current Assets 35.07K 32.78K $2.29K +6.98%
    Property Equipment Net 51.73K 52.40K $-674.00 -1.29%
    Operating Lease Right Of Use Assets 17.92K 19.00K $-1.08K -5.68%
    Current Liabilities Accounts Payable 40.38K 40.38K $0.00 +0.00%
    Loss from Operations -137.36K -145.58K $8.22K +5.65%
    Other Income, Net 8.91K 12.61K $-3.70K -29.34%
    Net Loss -128.45K -128.45K $0.00 +0.00%
    Prepaid Expenses and Other Current Assets 35.07K 32.78K $2.29K +6.98%
    Property and Equipment, Net 51.73K 52.40K $-674.00 -1.29%
    Accounts Payable 40.38K 40.38K $0.00 +0.00%

    💼 Business Developments:

    • Partnership
    • Acquisition: Not available
    • Licensing: Not available
    • Regulatory Approval
    • Executive Changes: Not available

    Structured Data:

    • Company Name: DENALI THERAPEUTICS INC.
    • Ticker Symbol: DNLI

Search

News categories